Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05064540 · ClinicalTrials.gov registry record · NA

JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization

A NA study of AAA - Abdominal Aortic Aneurysm and AAA, sponsored by Endologix.

Recruiting
Registry status
NA
Development phase
450
Enrollment target
20
Study locations

NCT05064540: Recruiting NA study of AAA - Abdominal Aortic Aneurysm and AAA, sponsored by Endologix.

NCT05064540 is a NA study of AAA - Abdominal Aortic Aneurysm and AAA that is actively recruiting participants, run by Endologix. The registered enrollment target is 450 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05064540, a NA study of AAA - Abdominal Aortic Aneurysm and AAA, is actively recruiting participants, sponsored by Endologix.

RECRUITING
Registry status
NA
Development phase
450 participants
Enrollment target
20
Study locations

Study Summary

Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).

Primary Outcome

Composite endpoint consisting of aneurysm-related death, aneurysm rupture, conversion to open surgery, type I and III endoleaks, device migration (\>10mm), aneurysm sac enlargement (\>5mm), occlusion, and freedom from device-related interventions

Interventions

  • DEVICE Alto Abdominal Stent Graft System
  • DEVICE FDA Approved EVAR AAA Graft Systems

Study Locations (20)

Florida

  • Jacksonville Center for Clinical Research - Jacksonville
  • Radiology and Imaging Specialists - Lakeland
  • Baptist Hospital of Miami, Miami Cardiac and Vascular Institute - Miami

Arkansas

  • Washington Regional Medical Center - Fayetteville
  • Central Arkansas Veterans Healthcare System - Little Rock

California

  • The Regents of the University of California, San Diego - La Jolla
  • Veterans Affairs San Diego Healthcare System - San Diego

New York

  • Icahn School of Medicine at Mount Sinai - New York
  • Feinstein Institutes for Medical Research (Staten Island University Hospital/Northwell Health) - Staten Island

Ohio

  • The Cleveland Clinical Foundation - Cleveland
  • The Ohio State University - Columbus

Alabama

  • Huntsville Hospital - Huntsville

Arizona

  • University of Arizona - Tucson

District of Columbia

  • MedStar Washington Hospital Center - Washington D.C.

Trial Details

FieldValue
Enrollment Target 450 participants
Start Date 2021-09-20
Est. Completion 2031-03
Phase NA
Endologix

17 total trials

What NCT05064540 shows while recruiting

NCT05064540 is an interventional study that assigns participants to a tested intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (68% lower).

The record links to 2 conditions, with AAA - Abdominal Aortic Aneurysm appearing as the primary indexed condition, and to 2 interventions - of which Alto Abdominal Stent Graft System is the first listed.

NCT05064540 names 20 study sites across 14 states, led by Florida, Arkansas, California.

Frequently Asked Questions

What is clinical trial NCT05064540 about?

NCT05064540 is a clinical study titled "JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization". Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, a...

What is the current status of trial NCT05064540?

This trial is currently recruiting. It is a NA study. The enrollment target is 450 participants. The study started on 2021-09-20. Estimated completion is 2031-03.

What conditions does trial NCT05064540 study?

This clinical trial studies the following conditions: AAA - Abdominal Aortic Aneurysm, AAA.

What interventions are being tested in trial NCT05064540?

The interventions under investigation include: Alto Abdominal Stent Graft System (DEVICE), FDA Approved EVAR AAA Graft Systems (DEVICE).

Who is sponsoring clinical trial NCT05064540?

This trial is sponsored by Endologix, which has 17 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05064540 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for AAA - Abdominal Aortic Aneurysm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05064540's enrollment target sits among peer trials

450 225th of 2000 higher than 1,769 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00515060 · 450 participants

    Psychophysical Studies of Cancer Therapy Pain

  • NCT01257269 · 450 participants

    Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)

  • NCT03047161 · 450 participants

    Electrophysiology of Fetal Arrhythmia

  • NCT03269630 · 450 participants

    New Orleans Pulmonary Hypertension Biobank

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05064540, the US trial registry maintained by the National Library of Medicine. NCT05064540 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.